mRNA Vaccines: GATES’ BIG PHARMA GSK earns $320M without Risks! After BioNTech-Pfizer settling with CureVac thanks to a Deal on mRNA-based Prophylactics
How Gates-controlled Big Pharma profits from COVID vaccines without risking anything
Introduction by Fabio Giuseppe Carlo Carisio
Big Pharma GSK, one of the most powerful Big Pharma companies in the world, controlled by Bill Gates through lavish investments and through CEO Emma Walmsley (a non-executive director of Microsoft), will rake in hundreds of millions of dollars on mRNA COVID vaccines without exposing itself to even the slightest risk of lawsuits over adverse reactions to these new and extremely dangerous gene therapies.
In an initial indirect lawsuit with Pfizer-Biontech, it has already secured $320 million, but other disputes are pending in a global legal battle over the intellectual property rights of the mRNA technology patent.
That Gates is behind this multi-billion-euro whirlwind is proven by multiple coincidences linking GSK with Pfizer, which was its strategic partner in the creation of the Consumer Healthcare joint venture that later culminated in the spin-off of the new British multinational Haleon.
In March 2025, Pfizer sold its entire stake in Haleon for approximately £2.5 billion ($3.24 billion), marking its complete exit from the consumer healthcare firm it helped create through its 2019 joint venture with GSK.
But that’s not the only curious thing. The WHO’s COVAX plan for the distribution of COVID-19 vaccines in developing countries, although it ultimately failed due to the refusal of many African and Latin American nations to conduct mass vaccination campaigns, revealed multiple conflicts of interest.
The COVAX plan was proposed and administered by the Gates-founded NGOs GAVI Alliance and CEPI, who recruited, coincidentally, a GSK manager to manage it.
Among the main funders was the Biden administration’s US government, with $4 billion, which tied its contribution to the purchase of 500 million doses of Comirnaty, the COVID-19 vaccine produced by Pfizer of New York together with BionTech, another company in which Bill Gates had invested before the pandemic.
And that’s not all.
The Bill & Melinda Gates Foundation awarded European Commission President Ursula von der Leyen, who has been under investigation for the scandal, shamefully shelved by the judges, for her contribution to Covax vaccines: purchases of Pfizer vaccines negotiated privately and secretly with her friend Albert Bourla, CEO of the New York pharmaceutical company.
In light of these intrigues, it is therefore clear that the alleged patent infringements on mRNA genetic serums could not have been unknown to Bill Gates, a major shareholder in GSK, a financier of BionTech and Moderna.
This is why the current lawsuits appear to be a way for the major Big Pharma company, controlled by the Microsoft guru, to gain a share of the pie without soiling its hands with the blood of those who died or were injured.
Fabio Giuseppe Carlo Carisio – Gospa News director
GSK collects $320M as BioNTech, Pfizer settle mRNA patent spat with CureVac
Excerpt from the article of Fraiser Kansteiner – Originally published on Fierce Pharma
All links to previous Gospa News artcile have been added in the aftermath by virtue of the ties with the topics covered
Pfizer and BioNTech have settled a patent lawsuit brought by CureVac in the U.S. The deal will see BioNTech pay out cash and extend royalties from sales of its Pfizer-partnered COVID-19 vaccine to CureVac and its mRNA licensee GSK in exchange for a non-exclusive license to make, import and sell mRNA-based prophylactics domestically.
GSK’s involvement in the case is complicated and unrelated to separate litigation it has brought against Pfizer and BioNTech over similar infringement claims.
GSK and CureVac partnered on the development of mRNA vaccines in 2020 and restructured their team-up into a new licensing agreement last July. Under the amended collaboration, GSK handed CureVac 400 million euros ($466 million) upfront for full rights to develop, manufacture and sell mRNA vaccines for COVID and flu.
But a rift has apparently emerged since BioNTech moved to buy out CureVac for $1.2 billion in June, with GSK recently intervening in its partner’s patent litigation with Pfizer and BioNTech over concerns that CureVac would not pursue the case properly.
Under the new settlement with CureVac and GSK, BioNTech will pay $370 million and supply an ongoing 1% royalty payment on U.S. sales of Pfizer and BioNTech’s licensed products, effective at the beginning of 2025, BioNTech said in an Aug. 8 press release.
GSK will receive $320 million of the settlement payment upfront in cash,
GSK will receive $320 million of the settlement payment upfront in cash, the British drugmaker said in a Friday press release (PDF). As for the other $50 million, GSK is realizing that value through an amendment to its own CureVac agreement. Under the amended pact, GSK will benefit from a “significant reduction” in the amount of royalties it will have to pay CureVac on potential future mRNA vaccines for flu, COVID or a combination of the two, according to the release.
Should the CureVac acquisition close, GSK is in line to receive another $130 million from BioNTech and a 1% royalty on global sales of applicable mRNA products. Crucially, the completion of BioNTech’s buyout would also knock out remaining litigation brought by CureVac against Pfizer and BioNTech outside the U.S.
Meanwhile, once the merger of the German mRNA specialists either goes through or fails, CureVac itself will also receive $370 million and a 1% royalty on U.S. sales of Pfizer and BioNTech’s vaccines.
The resolution doesn’t eliminate the separate mRNA patent litigation case
While GSK benefits from the CureVac settlement, the resolution doesn’t eliminate the separate mRNA patent litigation case the British pharma giant brought against Pfizer and BioNTech last April, GSK said in its release.
In that legal action, filed in Delaware federal court, GSK accused Pfizer and BioNTech of infringing five patents related to mRNA vaccine technology.
GSK claimed at the time that the relevant research on the platform had been conducted “more than a decade” before the COVID-19 pandemic and rightly belonged to GSK after it purchased a “substantial portion” of Novartis’ global vaccine business in 2015.
Even Moderna inside the disputes over mRNA intellectual property
CureVac, for its part, first brought its case against BioNTech back in 2022, initially accusing its German mRNA compatriot of treading on four patents related to the engineering of mRNA molecules, including sequence modifications for stability and mRNA vaccine formulations specific to SARS-CoV-2. Then it accused BioNTech of violating at least 10 patents related to mRNA vaccine technology as of July 2023.
While CureVac’s patent litigation saga is wrapping up, disputes over mRNA intellectual property continue to roil elsewhere.
Warfare between Big Pharma Giants Moderna & Pfizer on mRNA Vaccines’ Nanoparticles
Aside from GSK’s separate and ongoing mRNA litigation against Pfizer and BioNTech, the British drugmaker has also sued Moderna on similar claims. And Moderna has filed suit against Pfizer and BioNTech over alleged patent infringement, too. Several smaller mRNA players have gotten into the mix, as well.
by Fraiser Kansteiner – Originally published on Fierce Pharma
RELATED TOPICS
